{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:37:38Z","timestamp":1785551858845,"version":"3.56.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015303","name":"Otsuka Pharmaceutical Development and Commercialization Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015303","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014013","name":"UKRI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology Letters"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.toxlet.2022.11.017","type":"journal-article","created":{"date-parts":[[2022,11,26]],"date-time":"2022-11-26T09:29:14Z","timestamp":1669454954000},"page":"148-151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Activation of tolvaptan-responsive T-cell clones with the structurally-related mozavaptan"],"prefix":"10.1016","volume":"373","author":[{"given":"Sean","family":"Hammond","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merrie","family":"Mosedale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean J.","family":"Naisbitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxlet.2022.11.017_bib1","doi-asserted-by":"crossref","unstructured":"Cao, X., et al., 2022. Benzodiazepine Derivatives as Potent Vasopressin V2 Receptor Antagonists for the Treatment of Autosomal Dominant Kidney Disease. 2022.","DOI":"10.1021\/acs.jmedchem.2c00567"},{"key":"10.1016\/j.toxlet.2022.11.017_bib2","first-page":"1","article-title":"Therapeutic advances in ADPKD: the future awaits","author":"Capuano","year":"2021","journal-title":"J. Nephrol."},{"issue":"11","key":"10.1016\/j.toxlet.2022.11.017_bib3","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1021\/acs.chemrestox.0c00328","article-title":"Tolvaptan- and Tolvaptan-metabolite-responsive T cells in patients with drug-induced liver injury","volume":"33","author":"Gibson","year":"2020","journal-title":"Chem. Res. Toxicol."},{"issue":"1","key":"10.1016\/j.toxlet.2022.11.017_bib4","first-page":"95","article-title":"Shedding light on drug-induced liver injury: activation of T cells from drug naive human donors with tolvaptan and a hydroxybutyric acid metabolite","volume":"179","author":"Hammond","year":"2021","journal-title":"Toxicol. Sci."},{"issue":"8","key":"10.1016\/j.toxlet.2022.11.017_bib5","first-page":"695","article-title":"Influence of chemical structure on hypersensitivity reactions induced by antiepileptic drugs: the role of the aromatic ring","volume":"31","author":"Handoko","year":"2008","journal-title":"Medicine"},{"issue":"suppl_1","key":"10.1016\/j.toxlet.2022.11.017_bib6","article-title":"FP806 INITIAL RESULTS FROM A PHASE 2 TRIAL OF THE SAFETY AND EFFICACY OF BARDOXOLONE METHYL IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE AND IGA NEPHROPATHY","volume":"33","author":"Pergola","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.toxlet.2022.11.017_bib7","unstructured":"pharmaceuticals, C., Centessa Pharmaceuticals Makes Strategic Decision to Discontinue Clinical Development of Lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD). \u3008https:\/\/investors.centessa.com\/news-releases\/news-release-details\/centessa-pharmaceuticals-makes-strategic-decision-discontinue\u3009 Accessed 30\/07\/2022, 2022."},{"issue":"1","key":"10.1016\/j.toxlet.2022.11.017_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2369-14-233","article-title":"TNF-\u03b1 blockade is ineffective in animal models of established polycystic kidney disease","volume":"14","author":"Roix","year":"2013","journal-title":"BMC Nephrol."},{"issue":"2","key":"10.1016\/j.toxlet.2022.11.017_bib9","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.tox.2004.12.016","article-title":"Cross-reactivity among drugs: clinical problems","volume":"209","author":"Romano","year":"2005","journal-title":"Toxicology"},{"issue":"1","key":"10.1016\/j.toxlet.2022.11.017_bib10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1365-2222.2006.02402.x","article-title":"T cell\u2010mediated hypersensitivity to quinolones: mechanisms and cross\u2010reactivity","volume":"36","author":"Schmid","year":"2006","journal-title":"Clin. Exp. Allergy"},{"issue":"2","key":"10.1016\/j.toxlet.2022.11.017_bib11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s40620-019-00679-y","article-title":"ADPKD current management and ongoing trials","volume":"33","author":"Testa","year":"2020","journal-title":"J. Nephrol."},{"issue":"25","key":"10.1016\/j.toxlet.2022.11.017_bib12","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N. Engl. J.\u00a0Med."},{"issue":"20","key":"10.1016\/j.toxlet.2022.11.017_bib13","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.toxlet.2022.11.017_bib14","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s40264-015-0327-3","article-title":"Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database","volume":"38","author":"Watkins","year":"2015","journal-title":"Drug Saf."},{"issue":"2","key":"10.1016\/j.toxlet.2022.11.017_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11095-019-2726-0","article-title":"Comparison of the hepatotoxic potential of two treatments for autosomal-dominant polycystic kidney diseaseusing quantitative systems toxicology modeling","volume":"37","author":"Woodhead","year":"2020","journal-title":"Pharm. Res."}],"container-title":["Toxicology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037842742201801X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037842742201801X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T05:29:15Z","timestamp":1759901355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S037842742201801X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":15,"alternative-id":["S037842742201801X"],"URL":"https:\/\/doi.org\/10.1016\/j.toxlet.2022.11.017","relation":{},"ISSN":["0378-4274"],"issn-type":[{"value":"0378-4274","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activation of tolvaptan-responsive T-cell clones with the structurally-related mozavaptan","name":"articletitle","label":"Article Title"},{"value":"Toxicology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxlet.2022.11.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}